Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price objective boosted by investment analysts at Needham & Company LLC from $255.00 to $282.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 13.93% from the company’s previous close.
Several other equities analysts have also recently issued reports on JAZZ. Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. Bank of America increased their target price on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Raymond James Financial reaffirmed an “outperform” rating and issued a $239.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Royal Bank Of Canada boosted their price objective on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $259.06.
Get Our Latest Stock Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Price Performance
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. Sell-side analysts predict that Jazz Pharmaceuticals will post 21.9 EPS for the current fiscal year.
Insider Transactions at Jazz Pharmaceuticals
In other news, Director Rick E. Winningham sold 2,741 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.57, for a total transaction of $662,143.37. Following the completion of the transaction, the director owned 9,567 shares in the company, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the sale, the director directly owned 366,682 shares in the company, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,098 shares of company stock valued at $3,131,906 over the last three months. 4.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Capital World Investors grew its position in Jazz Pharmaceuticals by 4.4% in the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after purchasing an additional 111,735 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after buying an additional 191,637 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after buying an additional 1,129,995 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after buying an additional 517,514 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 3.1% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,677,132 shares of the specialty pharmaceutical company’s stock worth $285,113,000 after buying an additional 50,996 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- Buyback Boom: These 3 Companies Are Betting Billions on Their Own Stocks
- Costco’s Cooling Comp Sales Keep Stock Stuck in Neutral for Now
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
